We scan new podcasts and send you the top 5 insights daily.
Edward van Vaesel says European biotechs often run first human trials in the US but also Australia, where patient access is faster, costs are lower and tax benefits exist. He ties this to Europe's fragmented 27-country trial bureaucracy. That makes Europe less attractive for early clinical development.
Unlike the unified US system, running a multi-country clinical trial in Europe is a bureaucratic nightmare. A single trial can require three slightly different protocols for Switzerland, the UK, and Spain, for example, creating significant delays, costs, and complexity for investigators.
Edward van Vaesel says Europe generates nearly as much science and IP as the US, but lacks the capital markets, risk appetite and trial infrastructure to translate it. He notes European companies often run first trials in the US or Australia because patient access is faster and cheaper.
Biotechs are strategically using Australia's speed to their advantage. By starting a Phase 1 trial in Australia in parallel with a US IND application, they can collect early data from healthy volunteers and a small patient cohort. This data can then be used to strengthen the US filing, potentially justifying a higher starting dose or an improved trial design.
Australia's reputation as a top FIH destination is a carefully constructed ecosystem tailored for small biotechs. It combines dedicated Phase 1 units, a powerful 43.5% R&D tax refund, and a rapid notification system, making it the ideal location for healthy volunteer studies run by emerging companies.
Biotech developers are migrating toward transnational development models that execute early clinical de-risking in regions like China, Australia, or the UK. This approach accelerates progression while maintaining strict data quality standards required by Western regulators for commercial approval.
US biotechs increasingly use sites like Australia to accelerate development, as Create Medicines did by moving from concept to clinic in under 12 months. What was once viewed with suspicion is now a key strategy to generate data faster and more cheaply, competing with the speed of China's ecosystem.
The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.
The global landscape for early-stage clinical trials is shifting, with the U.S. at risk of falling behind. Australia has established itself as a trendsetter and a primary destination for first-in-human studies, while China is accelerating development by leveraging "China speed" and a higher regulatory risk tolerance.
Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.
Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.